Home Cart Sign in  
Chemical Structure| 81403-68-1 Chemical Structure| 81403-68-1

Structure of Alfuzosin HCl
CAS No.: 81403-68-1

Chemical Structure| 81403-68-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Alfuzosin HCl is an antagonist of α1 adrenergic receptor used to treat benign prostatic hyperplasia (BPH).

Synonyms: SL 77499-10; Alfuzosin(hydrochloride); Uroxatral

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Alfuzosin HCl

CAS No. :81403-68-1
Formula : C19H28ClN5O4
M.W : 425.91
SMILES Code : O=C(C1OCCC1)NCCCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)C.Cl
Synonyms :
SL 77499-10; Alfuzosin(hydrochloride); Uroxatral
MDL No. :MFCD00879135
InChI Key :YTNKWDJILNVLGX-UHFFFAOYSA-N
Pubchem ID :71764

Safety of Alfuzosin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Alfuzosin HCl

GPCR

Isoform Comparison

Biological Activity

Target
  • α-adrenergic receptor

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01685658 Renal Colic A... More >>cute Renal Colic Less << Phase 4 Suspended(same study already p... More >>ublished) Less << March 2018 France ... More >> CH d'Alès Alès, France, 30103 CHU de Nîmes - Hôpital Universitaire Carémeau Nîmes Cedex 9, France, 30029 Less <<
NCT01323998 - Completed - -
NCT01332487 - Completed - -
NCT01323998 - Completed - -
NCT01332487 - Completed - -
NCT01332435 - Completed - -
NCT01332435 - Completed - -
NCT01386983 - Completed - -
NCT00687388 Benign Prostatic Hyperplasia Phase 4 Withdrawn(in order to prepare ... More >>a new clinical trial to evaluate with pathological change) Less << - Korea, Republic of ... More >> Severance Hospital Seoul, Korea, Republic of, 120-752 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Asan Medical Center Seoul, Korea, Republic of, 138-736 Less <<
NCT00347061 Benign Prostatic Hyperplasia Phase 3 Completed - Japan ... More >> Sanofi-Aventis Tokyo, Japan Less <<
NCT00397397 - Unknown - Israel ... More >> Hillel Yaffe Medical Center Hadera, Israel, 38100 Less <<
NCT01435954 - Completed - -
NCT00451061 Renal Colic Phase 4 Unknown - Israel ... More >> Urology department, Soroka university medical center Not yet recruiting Beer-Sheva, p,o,box 151, Israel, 84101 Less <<
NCT01386983 - Completed - -
NCT01390870 - Completed - -
NCT01390870 - Completed - -
NCT02266537 Healthy Phase 1 Completed - -
NCT02977832 Benign Prostatic Hypertrophy W... More >>ith Outflow Obstruction Benign Prostatic Hyperplasia Less << Not Applicable Completed - Italy ... More >> Urology Department Fondazione IRCCS Policlinico San Matteo Pavia, Italy, 27100 Less <<
NCT00064649 Benign Prostatic Hyperplasia Phase 3 Terminated(Inability to recrui... More >>t required sample size.) Less << - United States, Colorado ... More >> University of Colorado Health Sciences Center Denver, Colorado, United States, 80010 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Columbia University New York, New York, United States, 10032 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Baylor College of Medicine Houston, Texas, United States, 77030 United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT00029822 Urinary Retention ... More >> Prostatic Hyperplasia Benign Prostatic Hypertrophy Less << Phase 3 Completed - -
NCT00399464 Prostatic Hyperplasia Phase 3 Completed - Japan ... More >> Sanofi-Aventis Tokyo, Japan Less <<
NCT00409357 Benign Prostatic Hyperplasia Phase 2 Completed - Japan ... More >> Sanofi-Aventis Tokyo, Japan Less <<
NCT00713739 Kidney Stones Phase 3 Unknown December 2012 United States, California ... More >> Naval Medical Center San Diego Recruiting San Diego, California, United States, 92134 Contact: Brian K Auge, M.D.    619-532-7200       Contact: Sean P. Stroup, M.D.    619-532-7200       Principal Investigator: Brian K. Auge, M.D.          Principal Investigator: Sean P. Stroup, M.D. Less <<
NCT00201630 Prostate Cancer Phase 3 Unknown - United States, New York ... More >> New York Prostate Institute Recruiting Oceanside, New York, United States, 11572 Contact: Betsy Guzman    516-632-3370    bguzman@snch.org    Principal Investigator: Louis Potters, MD Less <<
NCT00264017 - Completed - United States, Florida ... More >> Dattoli Cancer Center and Brachytherapy Research Institute Sarasota, Florida, United States, 34237 Less <<
NCT00427882 Prostatic Hyperplasia Phase 4 Completed - Korea, Republic of ... More >> Handok Seoul, Korea, Republic of Less <<
NCT00540891 Benign Prostatic Hyperplasia Phase 3 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT01418599 Healthy Phase 1 Completed - India ... More >> Bio Evaluation Centre, Torrent Pharmaceuticals Ltd., Village Bhat, Gandhinagar, Gujarat, India, 382428 Less <<
NCT01418586 Healthy Phase 1 Completed - India ... More >> Bio Evaluation Centre, Torrent Pharmaceuticals Ltd., Village Bhat, Gandhinagar, Gujarat, India, 382428 Less <<
NCT00563654 Prostatic Hyperplasia ... More >> Urinary Retention Acute Disease Less << Not Applicable Terminated - China ... More >> North District Hospital Hong Kong, China Less <<
NCT00280605 Prostatic Hyperplasia Phase 4 Completed - -
NCT00629720 Urinary Bladder Neurogenic Phase 3 Completed - United States, Pennsylvania ... More >> Sanofi-Aventis Administrative Office Malvern, Pennsylvania, United States, 19355 Serbia Sanofi-Aventis Administrative Office Belgrade, Serbia Less <<
NCT00583258 Kidney Stones Not Applicable Withdrawn - Canada, Ontario ... More >> St. Michael's Hospital Toronto, Ontario, Canada, M5B 1W8 Less <<
NCT00542165 BPH/LUTS/Sexual Functions Phase 4 Completed - Korea, Republic of ... More >> Sanofi-Aventis Seoul, Korea, Republic of Less <<
NCT00453908 Urinary Retention Phase 3 Terminated(The study was early... More >> terminated due to slow and difficult recruitment) Less << - Denmark ... More >> Sanofi-Aventis Hoersholm, Denmark Less <<
NCT01834729 Constipation Phase 2 Completed - United States, Minnesota ... More >> Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 Less <<
NCT00409227 Urolithiasis ... More >>Nephrolithiasis Ureterolithiasis Less << Phase 2 Unknown - Israel ... More >> Endourology unit Urology department Assaf Harofeh MC Recruiting Zerifin, Israel, 40700 Contact: yoram i siegel, MD    972-577-345408    ysiegel@asaf.health.gov.il    Principal Investigator: yoram i siegel, MD          Sub-Investigator: yaniv shilo, MD Less <<
NCT00941343 Prostatic Diseases Not Applicable Completed - Taiwan ... More >> Sanofi-Aventis Administrative Office Taipei, Taiwan Less <<
NCT00336921 Acute Urinary Retention Phase 2 Completed - China ... More >> Sanofi-aventis Beijing, China Less <<
NCT00549939 Neurogenic Urinary Bladder Phase 3 Completed - -
NCT00256399 BPH Erectile ... More >>Dysfunction Less << Not Applicable Unknown - United States, Ohio ... More >> University Hospitals of Cleveland Recruiting Cleveland, Ohio, United States, 44106 Contact: Ann M Serenko, MS, RN    216-844-3515    ann.serenko@uhhs.com    Contact: Allen D Seftel, MD    216-844-7728    adseftel@aol.com    Principal Investigator: Allen D Seftel, MD          Sub-Investigator: Martin Resnick, MD          Sub-Investigator: Donald Bodner, MD Less <<
NCT00454402 Prostatic Hyperplasia Phase 3 Terminated(Discontinued due to... More >> incomplete recruitment) Less << - Portugal ... More >> Sanofi-Aventis Lisbon, Portugal Less <<
NCT00549939 - Completed - -
NCT00290030 Prostatic Hyperplasia ... More >> Acute Urinary Retention Less << Phase 3 Completed - -
NCT00401661 Prostatic Hyperplasia Phase 4 Completed - Thailand ... More >> Sanofi-Aventis Bangkok, Thailand Less <<
NCT00486785 Prostatic Hyperplasia Phase 4 Completed - Colombia ... More >> Sanofi-Aventis Bogota, Colombia Ecuador Sanofi-Aventis Quito, Ecuador Guatemala Sanofi-Aventis Guatemala City, Guatemala Mexico Sanofi-Aventis Mexico, Mexico Less <<
NCT00637715 Benign Prostatic Hyperplasia Phase 4 Completed - Hungary ... More >> Sanofi-Aventis Budapest, Hungary Less <<
NCT00103402 Prostatitis Phase 3 Completed - United States, California ... More >> David Geffen School of Medicine at UCLA Los Angeles, California, United States, 90095 Stanford University Medical Center Stanford, California, United States, 94305 United States, Illinois Northwestern U. Feinberg School of Medicine Chicago, Illinois, United States, 60611 United States, Maryland University of Maryland Baltimore, Maryland, United States, 21201 United States, Massachusetts Harvard Medical School- Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Mississippi University of Mississippi Medical Center Jackson, Mississippi, United States, 39216 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Pennsylvania Temple University Philadelphia, Pennsylvania, United States, 19140 United States, Washington University of Washington- Harborview Medical Center Seattle, Washington, United States, 98108 Canada, Ontario Queen's University Kingston, Ontario, Canada, K7L 3N6 Less <<
NCT00696761 BPH Phase 4 Completed - -
NCT00836823 Benign Prostatic Hyperplasia ... More >> Lower Urinary Tract Symptoms Less << Phase 4 Completed - Korea, Republic of ... More >> Asan Medical Center, Ulsan College of Medicine Seoul, Korea, Republic of Samsung Medical Center Seoul, Korea, Republic of Less <<
NCT00576823 Hydronephrosis ... More >> Neurogenic Bladder Less << Phase 3 Completed - Bulgaria ... More >> Sanofi-Aventis Administrative Office Sofia, Bulgaria Canada Sanofi-Aventis Administrative Office Laval, Canada Estonia Sanofi-Aventis Administrative Office Tallin, Estonia India Sanofi-Aventis Administrative Office Mumbai, India Malaysia Sanofi-Aventis Administrative Office Kuala Lumpur, Malaysia Poland Sanofi-Aventis Administrative Office Warszawa, Poland Russian Federation Sanofi-Aventis Administrative Office Moscow, Russian Federation Serbia Sanofi-Aventis Administrative Office Belgrade, Serbia Singapore Sanofi-Aventis Aministrative Office Singapore, Singapore Slovakia Sanofi-Aventis Administrative Office Bratislava, Slovakia Taiwan Sanofi-Aventis Administrative Office Taipei, Taiwan Turkey Sanofi-Aventis Administrative Office Istanbul, Turkey Less <<
NCT00696761 - Completed - -
NCT00576823 - Completed - -
NCT00575913 Prostatic Diseases Phase 4 Completed - Thailand ... More >> Sanofi-Aventis Bangkok, Thailand Less <<
NCT00893113 - Completed - -
NCT00688948 Multiple Sclerosis ... More >> Bladder Dysfunction Less << Phase 2 Phase 3 Terminated(Lack of funding) - Canada, Nova Scotia ... More >> QE II Health Science Centre, Halifax Infirmary Halifax, Nova Scotia, Canada, B3H 3A7 Less <<
NCT00679315 Voiding Dysfunction Phase 2 Completed - Korea, Republic of ... More >> Chungnam National University Hospital Daejeon, Korea, Republic of Holy Family Hospital, The Catholic University of Korea Kyonggi-do, Korea, Republic of, 420-717 Pusan National University Hospital Pusan, Korea, Republic of, 602-739 Cheil General Hospital & Women's Healthcare Center, College of Medicine, Kwandong University Seoul, Korea, Republic of, 100-380 Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Anam Hospital, College of Medicine, Korea University Seoul, Korea, Republic of, 136-705 Kangnam St. Mary's Hospital, The Catholic University of Korea Seoul, Korea, Republic of, 137-701 Asan Medical Center, Ulsan College of Medicine Seoul, Korea, Republic of, 138-736 Less <<
NCT00893113 Erectile Dysfunction ... More >> Lower Urinary Tract Symptoms Less << Phase 3 Completed - United States, Maryland ... More >> Chesapeake Urology Research Associates Baltimore, Maryland, United States, 21204 Chesapeake Urology Research Associates Baltimore, Maryland, United States, 21237 Chesapeake Urology Research Associates Glen Burnie, Maryland, United States, 21061 Chesapeake Urology Research Associates Towson, Maryland, United States, 21204 Less <<
NCT03144596 Benign Prostatic Hyperplasia ... More >> Pupil Anomaly Choroid Disease Less << Phase 4 Completed - -
NCT00388271 Urinary Calculi Phase 3 Withdrawn(lack of funding) - Singapore ... More >> Urology Centre Singapore, Singapore Less <<
NCT00467467 Ureteral Stent Discomfort Phase 3 Completed - United States, Minnesota ... More >> University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<
NCT00177086 Kidney Calculi ... More >> Ureteral Calculi Colic Less << Phase 3 Completed - United States, Minnesota ... More >> University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.35mL

0.47mL

0.23mL

11.74mL

2.35mL

1.17mL

23.48mL

4.70mL

2.35mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories